Acenocoumarol

Known as: 3-(alpha-Acetonyl-P-nitrobenzyl)-4-hydroxycoumarin, Acenocoumarol [Chemical/Ingredient], Nitrophenylacetylethyl-4-hydroxycoumarine 
A 4-hydroxycoumarin derivative with anticoagulant activity. As a vitamin K antagonist, acenocoumarol inhibits vitamin K epoxide reductase, thereby… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1956-2017
02040608019562016

Related topics

Related topics

15 relations
Acenocoumarol:MCnc:Pt:Ser/Plas:QnAcenocoumarol:MCnt:Pt:Hair:QnIn Bloodagonists
(More)

Broader (1)

Anticoagulants

Narrower (5)

SinthromeSintromSyncoumarSyncumar
(More)

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
Acenocoumarol
standards characteristics
Anticoagulants
chemical synthesis
agonists
Sintrom

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies
BACKGROUND Standard treatment for venous thromboembolism (VTE) consists of a heparin combined with vitamin K antagonists. Direct… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006…
OBJECTIVES The objective of this study was to compare the predictive performance of bleeding risk-estimation tools in a cohort of… (More)
  • table 1
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Oral rivaroxaban for symptomatic venous thromboembolism.
BACKGROUND Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2009
Highly Cited
2009
A genome-wide association study of acenocoumarol maintenance dosage.
Several genome-wide association studies have been performed on warfarin. For acenocoumarol, the most frequently used coumarin in… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.
The aim of the study is to explore the contribution of genetic factors related either to drug metabolism (cytochrome P450 2C9) or… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2004
2004
Pharmacogenetics of acenocoumarol pharmacodynamics.
OBJECTIVE The aim of this study was to investigate the respective contribution of the different cytochrome P450 (CYP) 2C9 genetic… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study.
OBJECTIVES This trial evaluated the efficacy and safety of the combination of antiplatelet and moderate-intensity anticoagulation… (More)
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators.
BACKGROUND In patients with idiopathic deep venous thrombosis, continuing anticoagulant therapy beyond three months is associated… (More)
Is this relevant?
Highly Cited
1993
Highly Cited
1993
Bleeding complications in oral anticoagulant therapy. An analysis of risk factors.
BACKGROUND Insufficient data are available about the safety of oral anticoagulant therapy. The specialized organization of… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
1992
Highly Cited
1992
Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis.
BACKGROUND In most countries, heparin is used in the initial treatment of patients with deep-vein thrombosis. Well-designed… (More)
Is this relevant?